Biowaiver monographs for immediate release solid oral dosage forms based on Biopharmaceutics Classification System (BCS) literature data: Verapamil hydrochloride, propranolol hydrochloride, and atenolol

Journal of Pharmaceutical Sciences

Volumn 93, Issue 8, 2004, Pages 1945-1956

  Vogelpoel, H ^a   Welink, J ^b   Amidon, G L ^c   Junginger, H E ^d   Midha, K K ^e   Moller H ^f   Olling, M ^b   Shah, V P ^g   Barends, Dirk M ^a  

^a NATIONAL INSTITUTE FOR PUBLIC HEALTH AND THE ENVIRONMENT   (Netherlands)

^b Med Eval Bd of the Netherlands   (Netherlands)

^c UNIVERSITY OF MICHIGAN   (United States)

^d LEIDEN UNIVERSITY   (Netherlands)

^e UNIVERSITY OF SASKATCHEWAN   (Canada)

^f ABDA Bundesvereinigung Deutscher Apothekerverbande   (Germany)

^g CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

Author keywords

Atenolol; BCS; Biowaiver; Propranolol; Verapamil

Indexed keywords

ATENOLOL; CALCIUM CARBONATE; CALCIUM PHOSPHATE DIBASIC; CARBOXYMETHYLCELLULOSE; CELLULOSE; CROSCARMELLOSE SODIUM; CROSPOVIDONE; DODECYL SULFATE SODIUM; GELATIN; HYDROXYPROPYLCELLULOSE; HYDROXYPROPYLMETHYLCELLULOSE; LACTOSE; MAGNESIUM CARBONATE; MAGNESIUM STEARATE; POVIDONE; PROPRANOLOL; SILICON DIOXIDE; STARCH; STARCH GLYCOLATE SODIUM; STEARIC ACID; TALC; VEGETABLE OIL; VERAPAMIL;

CHEMICAL COMPOSITION; DRUG ABSORPTION; DRUG CLASSIFICATION; DRUG DISTRIBUTION; DRUG FORMULATION; DRUG METABOLISM; DRUG RELEASE; NETHERLANDS; NONHUMAN; QUALITATIVE ANALYSIS; REVIEW; TABLET;

EID: 3843072170     PISSN: 00223549     EISSN: None     Source Type: Journal    
DOI: 10.1002/jps.20131     Document Type: Note

References (58)

1. Amidon GL, Lennernäs H, Shah VP, Crison JR. 1995. A theoretical basis for a Biopharmaceutics Drug Classification: The correlation of in vitro drug product dissolution and in vivo bioavailability. Pharm Res 12:413-420.
2. U.S. Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research (CDER). 2000. Guidance for industry: Waiver of in vivo bioavailability and bioequivalence studies for immediate-release solid oral dosage forms based on a Biopharmaceutics Classification System.
3. Committee for Proprietary Medicinal Products (CPMP). 2001. Note for guidance on the investigation of bioavailability and bioequivalence.
4. Martindale. The extra pharmacopoeia, 31st edn. Royal Pharmaceutical Society, London, UK: Royal Pharmaceutical Society, London.
5. European Directorate for the Quality of Medicines. European pharmacopoeia, 4th edn. Strasbourg, France: European Directorate for the Quality of Medicines, Council of Europe, Strasbourg, France.
6. Merck Index CD-ROM version 12:1, Merck & Co. USA.
7. Chang ZL. In: Florey-Analytical profiles of drug substances, Vol. 17. London, UK: Academic Press.
8. Kasim NA, Whitehouse M, Ramachandran C, Bermejo M, Lennernäs H, Hussain AS, Junginger HE, Stavchansky SA, Midha KK, Shah VP, Amidon GL. 2004. Molecular properties of WHO essential drugs and provisional Biopharmaceutical Classification. Mol Pharm 1(1):85-96.
9. Hagers Handbuch der pharmazeutischen Praxis-Hrsg F von Bruchhausen...-5., vollst, neubearb. Aufl.-Berlin; Heidelberg; New York; London; Paris; Tokyo; Hong Kong; Barcelona; Budapest: Springer.
10. Doppenschmitt S, Spahn-Langguth H, Regardh CG, Langguth P. 1999. Role of P-glycoprotein-mediated secretion in absorptive drug permeability: An approach using passive membrane permeability and affinity to P-glycoprotein. J Pharm Sci 88(10):1067-1072.
11. Sandström R, Karlsson A, Knutson L, Lennernäs H. 1998. Jejunal absorption and metabolism of R/S-verapamil in humans. Pharm Res 15:856-862.
12. Winniwarter S, Bonham NM, Ax F, Hallberg A, Lennernäs H, Karlen A. 1998. Correlation of human jejunal permeability (in vivo) of drugs with experimental and theoretically derived parameters. A multivariate data analysis approach. J Med Chem 41:4939-4949.
13. Sandström R, Knutson TW, Knutson L, Jansson B, Lennernäs H. 1999. The effect of ketoconazole on the jejunal permeability and CYP3A metabolism of (R/S)-verapamil in humans. J Clin Pharmacol 48: 180-189.
14. eff-value for each enantiomet of (R,S)-verapamil. Pharm Res 13:246.
15. Wright MR, Jamali F. 1993. Bioequivalence: Stereochemical considerations. Clin Res Reg Aff 10(1):1-11.
16. Baky SH, Kirsten EB. 1981. Pharmacological and biochemical properties of drug substances, Vol. 3. In: Goldberg ME, editor. Verapamil. Washington DC: American Pharmaceutical Society, pp 226-261.
17. Home C, Stenzhorn G, Blume H, Knauf H, Mutschier E. 1992. Bioavailability study of two different verapamil formulations. Archiv Pharmazie 325(8):531-536.
18. Tsang YC, Pop R, Gordon P, Hems J, Spino M. 1996. High variability in drug pharmacokinetics complicates determination of bioequivalence: Experience with verapamil. Pharm Res 13:846-850.
19. Gierend M, Baarsma JP, Floris WW. 1990. Untersuchung zur Bioequivalenz von nichtretardiertem Verapamil. Umsetzung eines Monographieentwurfs an Beispiel Veramex 80. Med Klin 85(3): 132-140.
20. Hashiguchi M, Ogata H, Maeda A, Hirashima Y, Ishii S, Mori Y, Amamoto T, Handa T, Otsuka N, Irie S, Urae A, Urae R, Kimura R. 1996. No effect of high-protein food on the stereoselective bioavailability and pharmacokinetics of verapamil. J Clin Pharmacol 36(11):1022-1028.
21. Johnson JA, Akers WS. 1995. Influence of metabolites on protein binding of verapamil enantiomers. Br J Clin Pharmacol 39(5):536-538.
22. Czejka MJ, Zwoelfer N, Podesser B. 1992. Red blood cell partitioning of gallopamil, verapamil, and norverapamil. Farmaco 47(3):387-391.
23. McTavish D, Sorkin EM. 1989. Verapamil: An updated review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in hypertension. Drugs 38(1):19-76.
24. USP 26-NF 21. 2003. The United States Pharmacopeia-The National Formulary. Rockville, MD, 20852: The United States Pharmacopeial Convention, Inc.
25. Yu LX, Amidon GL, Polli JE, Zhao H, Mehta MU, Conner DP, Shah VP, Lesko LJ, Chen ML, Lee VHL, Hussain AS. 2002. Biopharmaceutics Classification System: The scientific basis for biowaiver extensions. Pharm Res 19(7):921-925.
26. USP 24-NF 19. 2000. The United States Pharmacopeia-The National Formulary. Rockville MD, 20852: The United States Pharmacopeial Convention, Inc.
27. Artursson P, Magnussen C. 1990. Epithelial transport of drugs in cell culture. II: Effect of extracellular calcium concentration on the paracellular transport of drugs of different lipophilicity across monolayers of intestinal (Caco-2) cells. J Pharm Sci 79(7):595-600.
28. Artursson P. 1990. Epithelial transport of drugs in cell culture. I: A model for studying the passive diffusion of drugs over intestinal absorptive (Caco-2) cells. J Pharm Sci 79(6):476-482.
29. Artursson P, Karlsson J. 1991. Correlation between oral drug absorption in humans and apparent drug permeability coefficients in human intestinal epithelial (Caco-2) cells. Biochem Biophysical Res Comm 175(3):880-885.
30. Walter E, Janich S, Roessler BJ, Hilfinger JM, Amidon GL. 1996. HT29-MTX/Caco-2 cocultures as an in vitro model for the intestinal epithelium: In vitro-in vivo correlation with permeability data from rats and humans. J Pharm Sci 85(10):1070-1076.
31. Pade V, Stavchansky S. 1997. Estimation of the relative contribution of the transcellular and paracellular pathway to the transport of passively absorbed drugs in the Caco-2 cell culture model. Pharm Res 14(9):1210-1215.
32. Ores M-C, Julian B, Bourre M, Meunier V, Roques C, Berger M, Boulenc X, Berger Y, Fabre G. 1998. Correlation between oral drug absorption in humans and apparent drug permeability in TC-7 cells, a human epithelial intestinal cell line: Comparison with the parental Caco-2 cell line. Pharm Res 15(5):726-733.
33. Walgren RA, Walle T. 1999. The influence of plasma binding on absorption/exsorption in the Caco-2 model of human intestinal absorption. J Pharm Pharmacol 51:1037-1040.
34. Lennernäs H, Nylander S, Ungell A-L. 1997. Jejunal permeability: A comparison between the using chamber technique and the single-pass perfusion in humans. Pharm Res 14(5):667-671.
35. Takamatsu N, Welage LS, Idkaidek NM, Liu D-Y, Lee PI-D, Hayashi Y, Rhie JK, Lennernäs H, Branett JF, Shah VP, Lesko L, Amidon GL. 1997. Human intestinal permeability of piroxicam, propranolol, phenylalanine, and PEG 400 determined by jejunal perfusion. Pharm Res 14(9): 1127-1132.
36. Dollery C. 1991. Therapeutic drugs, Vol. 2. Edinburgh, London: Churchill Livingstone. pp 272-278.
37. Informatorium Medicamentorum. 2001. Koninklijke Nederlandse Maatschappij ter bevordering der Pharmacie, 's Gravenhage: 976.
38. Huffman B, Lefkowitz RJ. 1996. Catecholamines, sympathomimetic drugs, and adrenergic receptor antagonists. In: Hardman JG, Limbird LE, Molinoff PB, Ruddon RW, Gilman AG, editors. Goodman & Gilman's the pharmacological basis of therapeutics, 9th edn., Chapter 10. New York, St. Louis: The Graw-Hill. pp 199-248.
39. Drug, Fact and Comparisons. 2001. 55th edn. New York, St. Louis. 477 p.
40. Drug Evaluations, annual. 1992. American Medical Association. 502 p.
41. Fade V, Stavchansky S. 1998. Link between drug absorption solubility and permeability measurements in Caco-2 cells. J Pharm Sci 87:1604-1607.
42. Čaplar V, Mikotic-Mihun Z, Hofman H, Kuftinec J, Kajfez F, Nagl A, Blazevic N. In: Flory-Analytical profiles of drug substances, Vol. 13. London, UK: Academic Press.
43. Moneghini M, Carcano A, Zingone G, Perissutti B. 1998. Studies in dissolution enhancement of atenolol Part I. Int J Pharm 175:177-183.
44. Schipper NGM, Varum KM, Stenberg P, Ocklind G, Lennernäs H, Artursson P. 1999. Chitosans as absorption enhancers of poorly absorbable drugs. 3: Influence of mucus on absorption enhancement. Eur J Pharm Sci 8:335-343.
45. Hilgendorf C, Spahn-Langguth H, Regardh CG, Lipka E, Amidon GL, Langguth P. 2000. Caco-2 versus Caco-2/HT29-MTX co-cultured cell-lines: Permeabilities via diffusion, inside- and outside-directed carrier-mediated transport. J Pharm Sci 89(1):63-75.
46. Collett A, Sims E, Walker D, He Y-L, Ayrton J, Rowland M, Warhurst G. 1996. Comparison of HT29-18-C1 and Caco-2 cell lines as models for studying intestinal paracellular drug absorption. Pharm Res 13(2):216-221.
47. Rubas W, Cromwell EM, Shahrokh Z, Villagran J, Nguyen T-N, Wellton M, Nguyen T-H, Mrsny RJ. 1996. Flux measurements across Caco-2 monolayers may predict transport in human large intestinal tissue. J Pharm Sci 85(2):165-169.
48. Lennernäs H, Ahrenstedt O, Ungell A-L. 1994. Intestinal drug absorption during induced net water absorption in man: A mechanistic study using antipyrine, atenolol, and enalaprilat. Br J Clin Pharmacol 37:589-596.
49. Lennernäs H. 1998. Human intestinal permeability. J Pharm Sci 87(4):403-410.
50. Lindahl A, Sandström R, Ungell A-L, Abrahamsson B, Knutson TW, Knutson L, Lennernäs H. 1996. Jejunal permeability and hepatic extraction of fluvastatin in humans. Clin Pharmacol Ther 60:493-503.
51. Fitzgerald JD. 1979. Pharmacological and biochemical properties of drug substances. In: Goldberg ME, editor. Atenolol, Vol. 2. American Pharmaceutical Association, Academy of Pharmaceutical Science, Washington, USA: Raven Press, USA. pp 98-147.
52. Fitzgerald JD. 1980. Pharmacology of antihypertensive drugs. In: Scriabine A, editor. Atenolol. American Pharmaceutical Association, Academy of Pharmaceutical Science, Washington, USA: Raven Press, USA. pp 263-273.
53. Heel RC, Brogden RN, Speight TM, Avery GS. 1979. Atenolol: A review of its pharmacological properties and therapeutic efficacy in angina pectoris and hypertension. Drugs 17:425-460.
54. Kirch W, Gorg KG. 1982. Clinical pharmacokinetics of atenolol. A review. Eur J Drug Metab Pharmacokin 7:81-91.
55. Boyd RA, Chin SK, Don Pedro O, Williams RL, Giacomini KM. 1989. The pharmacokinetics of the enantiomers of atenolol. Clin Pharmacol Ther 45: 403-410.
56. Melander A, Stenberg P, Liedholm H, Schersten B. 1979. Food induced reduction in bioavailability of atenolol. Eur J Pharmacol 16:327-330.
57. Mehvar R, Gross ME, Kreamer RN. 1990. Pharmacokinetics of atenolol enantiomers in humans and rats. J Pharm Sci 79(10):881-885.
58. Blume EJ, Schug BS. 1999. The biopharmaceutical classification system (BCS): Class III drugs-Better candidates for BA/BE waiver? Eur J Pharm Sci 9:117-121.